Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-finding study of subcutaneous IPP-201101 in active systemic lupus erythematosus
2007-004892-21Phase 2Completed
- Sponsor
- ImmuPharma
- Start
- Dec 2007
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of forigerimod in systemic lupus erythematosus (SLE) (3 arms), sponsored by ImmuPharma. Primary endpoint: Combined clinical response at week 12. Started Dec 2007; status: completed.
02
Drugs
forigerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2007-004892-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004892-21.